Surgical management of massive upper gastrointestinal bleeding after failed medical treatment may be hazardous because ofdiffuse bleeding from several sites, further complicated 'in some patients by intercurrent disease, age, or previous surgery. Experience with combined somatostatin and octreotide therapy in five such patients is described. All were treated initially with either intravenous somatostatin (250 [tg/hour) or octreotide (Sandostatin) (50 ig/hour) for periods ranging from three to five days, after which they were given subcutaneous octreotide (50 or 100 ig three times daily). Bleeding was controlled by this regimen in all cases. The patients were all discharged from hospital on either ranitidine (n=4) or omeprazole (n= 1). Repeat endoscopy at the end of the treatment period with somatostatin and octreotide (n= 1) or four weeks after discharge (n=3) showed complete healing of the bleeding sites. Somatostatin and octreotide may be of value in controlling severe upper gastrointestinal bleeding in patients in whom surgery is hazardous because of bleeding from several peptic lesions further complicated in some by intercurrent disease or age.
In most patients who present with upper gastrointestinal haemorrhage, bleeding stops spontaneously and does not recur in the short term after beginning supportive treatmentgenerally, bed rest and administration of H2-blockers. A few patients continue to bleed or rebleed, however, and there can be little doubt that in most of these surgery should be undertaken to control the haemorrhage. Furthermore, several factors have been implicated as accurate indicators of early recurrent bleeding, including the presence of a visible vessel in the ulcer crater, age greater than 60 years, presentation with haematemesis, and a haemoglobin concentration at admission of less than 8 g/100 ml.' 2 When all of these factors are present, rebleeding occurs in 71% of patients, an event which significantly influences mortality. 3 In the presence of these risk factors, early surgical intervention should be considered to prevent recurrent haemorrhage and, it is hoped, to improve survival. 3 In some patients, despite continued or recurrent haemorrhage, surgical intervention carries a high risk because of their age or physical condition or the presence of multiple bleeding lesions that require a much more radical procedure than would be carried out for a single peptic ulcer. Furthermore, in some patients, previous gastric operations may make surgery difficult. In these circumstances there is a need for an effective, safe medical treatment to control bleeding and promote healing. We The patient was discharged from hospital 48 hours later on ranitidine (150 mg twice daily) and Gaviscon (10 ml after meals) and underwent endoscopy as an outpatient six weeks later. The oesophagus, stomach, and duodenum were all of normal appearance and histological examination of biopsy specimens showed complete healing with no evidence of gastritis or duodenitis. PATIENT 2 A 78 year old woman with a previous history of heart failure, for which she was being treated with digitalis and diuretics, presented with a haematemesis and melaena. On admission to hospital she was shocked (blood pressure 90/60 mm Hg; pulse 120 bpm), had dyspnoea because of a chest infection, and had a haemoglobin concentration of g/100 ml. Upper gastrointestinal endoscopy showed five ulcers in the antrum of the stomach, all of which were bleeding actively. The remainder ofthe stomach, oesophagus, and duodenum were normal. In view of her age, chest infection, and past history of heart failure she was not considered fit enough for subtotal gastrectomy. She was transfused 6 U blood and begun on a continuous intravenous infusion of somatostatin (250 [ig/hour) for five days. No further episodes of haematemesis occurred and she remained haemodynamically stable, with a haemoglobin value of 11 g/100 ml throughout the five day infusion. She did, however, continue to pass fresh melaena stools for approximately 72 hours. On stopping the somatostatin infusion she was given subcutaneous octreotide (100 Fg twice daily) for a further five days and was discharged from hospital on the 10th day on ranitidine (150 mg twice daily). A repeat endoscopy was carried out four weeks later and no abnormality was observed in the stomach, oesophagus, or duodenum. Biopsy specimens of the antrum and body of the stomach were histologically normal. PATIENT 3 A 93 year old woman presented with acute peritonitis. At laparotomy she was found to have an anterior perforated duodenal ulcer which was treated with simple suture and peritoneal lavage. After surgery she was begun on ranitidine; initially intravenously and then orally (150 mg twice daily). On the evening before her proposed discharge home, she experienced a massive gastrointestinal bleed with haematemesis, melaena, and profound hypotension. She was given 5 U blood and underwent a further laparotomy which showed that the previous perforation was completely healed. The duodenum was opened, showing a large posterior ulcer, distinct from the anterior one which had perforated previously. The posterior ulcer was under run with non-absorbable sutures, and a truncal vagotomy and pyloroplasty performed. She had a further 3 U blood transfused postoperatively and was continued on ranitidine.
Initially the patient seemed to do well, but on the third day after surgery she had a further life threatening gastrointestinal haemorrhage with melaena, passage offresh blood up the nasogastric tube, and a severe systemic disturbance (blood pressure 80/60 mm Hg; pulse 120 bpm).
Resuscitation was carried out with further transfusions ofblood and colloid, but it was considered inappropriate because of her age to subject her to endoscopy or further surgery, which probably would have necessitated a gastrectomy. Although the evidence is circumstantial the rapid onset of recurrent bleeding from at least two previously diagnosed duodenal ulcers suggests that this patient may have had multiple peptic lesions. She was begun on intravenous octreotide (50 [ig/hour) after which she had no further gastrointestinal haemorrhage and her haemoglobin values remained stable. After 72 hours the octreotide was stopped and she was begun on 100 ig subcutaneously of the somatostatin analogue three times daily. This regimen was continued for five days and then tailed off so that on day 6 she received 100 ,ug twice daily, and on day seven a single subcutaneous dose of 100 rig. Her haemoglobin concentrations remained stable and she was discharged home nine days after her second laparotomy on ranitidine (150 mg twice daily). She was reviewed four weeks later when she seemed well with no fall in her haemoglobin values. In view of her age it was decided not to submit her to endoscopy but to maintain her on H2-blockers. PATIENT 4 A 23 year old man presented with a four week history of diarrhoea, bloating, and weight loss. Rectal examination showed a large mass at 6 cm which seemed to be fixed within the pelvis. Rectal biopsy specimen confirmed the mass to be an adenocarcinoma. A defunctioning sigmoid colostomy was performed with a view to pelvic exenteration later after computed tomogram of the pelvis and intravenous urography had established the extent of the tumour. Six days after the operation the patient underwent a sudden noticeable deterioration with severe abdominal pain, pyrexia, tachycardia, and hypotension. Laparotomy showed a stercoral perforation of the colon immediately proximal to the stoma, with faecal peritonitis. A total colectomy with end ileostomy was carried out and the abdomen lavaged with tetracycline in saline (lg/l). After surgery the patient was begun on prophylactic heparin (5000 IU, twice daily).
Seven days after the second operation the patient experienced a sudden haematemesis with passage of altered blood via the stoma, and became profoundly hypotensive (blood pressure 80/50 mm Hg, pulse 120 bpm). He With respect to massive continuous bleeding or in the presence of stigmata suggesting a high risk ofearly recurrent haemorrhage, somatostatin was significantly more effective than placebo in controlling haemorrhage and reducing the need for surgical intervention in such patients.56 In the present study in patients with multiple peptic lesions, although a different group to those with single lesions and either stigmata or continuous bleeding, somatostatin and ocreotide were effective in controlling bleeding and maintaining haemostasis in these high risk patients. Since most deaths from peptic ulceration, which has not changed in the past 20 years, occur in these high risk patients, somatostatin and octreotide may reduce mortality by avoiding the need for surgical intervention. However, the hypothesis can only be confirmed by a randomised controlled trial of somatostatin and octreotide v surgery or endoscopic intervention in patients with massive continued haemorrhage or stigmata suggesting a high risk of recurrent bleeding, in whom prognosis is poor, and hence mortality relatively high. 
